香港, 2025年10月29日 - (亚太商訊) - 2025年10月28日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"，股票代码：1788.HK）作为联席保荐人、整体协调人、保荐人兼整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人，助力中国领先的企业级大模型人工智能应用解决方案提供商滴普科技股份有限公司（"滴普科技"，股票代码：1384.HK）于10月28日在香港联交所主板成功上市。滴普科技本次港股成功上市，是国泰海通集团充分整合境内外资源的又一典范之作。在本项目中，国泰君安国际充分发挥其沟通协调与执行能力，开展了精准高效的路演推介与深入的投资者沟通，成功助力本次IPO成为中国企业级大模型人工智能应用解决方案领域募资规模领先的港股项目，进一步巩固了滴普科技在企业级大模型人工智能解決方案市场的竞争优势。本次项目的成功执行，彰显了国泰君安国际在港股IPO市场，尤其是服务新经济及特专科技企业方面的领先地位。本次发行最终定价为每股26.66港元，总发售股数达2,663.2万股，总集资额约为7.1亿港元。香港公开发售录得踊跃认购，认购倍数约为7,569倍，显示出市场对滴普科技在企业级人工智能解决方案领域领先地位及未来增长潜力的高度认可。公司计划将募集资金用于以下战略方向：约40%用于提升研发能力；约30%用于扩大在中国的销售网络及客户群；约15%用于海外业务扩张；约5%用于潜在投资及并购；10%将作为营运资金及一般公司用途。此资金规划将为滴普科技巩固技术壁垒和加速商业化进程提供坚实动力。早在2021年，国泰君安国际联合领投滴普科技1亿美金B轮融资，2022年认缴完毕，充分展现了公司前瞻性地布局人工智能赛道、精准把握高成长企业潜力的战略眼光，也为后续助力滴普科技登陆港股市场奠定了坚实的合作基础。未来，国泰君安国际将继续凭借其专业的金融服务能力，致力于为更多创新科技企业连接全球资本市场。关于滴普科技滴普科技是中国领先的企业级大模型人工智能应用解决方案提供商，通过其FastData企业级数据智能解决方案和FastAGI企业级人工智能解决方案助力企业大规模高效整合数据、决策及运营。以2024年收入计，滴普科技在中国企业级大模型人工智能应用解决方案市场排名第五。其解决方案已实现多个垂直行业的规模商业化落地，覆盖消费零售、制造、医疗及交通等领域。截至2025年6月30日，滴普科技为各行业累计283名企业用户提供服务，复购客户占比33.2%，体现了高度的客户黏性及客户满意度。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) – October 28, As the  joint sponsor, overall coordinator, sponsor-overall coordinator, joint global coordinator, joint bookrunner and joint lead manager, Guotai Junan International Holdings Limited (“GTJAI”, stock code: 1788.HK), a company of Guotai Haitong Group, facilitated the successful listing of Deepexi Technology Co., Ltd. (“Deepexi Technology”, stock code: 1384.HK), a leading enterprise large model AI application solution provider in China, on the main board of the Hong Kong Stock Exchange on October 28.The successful listing of Deepexi Technology exemplifies Guotai Haitong Group’s strength in integrating domestic and international resources.  In this project, GTJAI fully leveraged its communication, coordination and execution capabilities to conduct precise and efficient roadshows and in-depth investor engagement. This successfully positioned the IPO as the leading Hong Kong-listed project in terms of fundraising scale of China's enterprise large model AI application solution sector, further solidifying Deepexi Technology’s competitive edge in the enterprise large model AI application solution market. The successful execution of this project underscores GTJAI’s leading position in the Hong Kong IPO market, particularly in serving new economy and specialized technology enterprises.The final offering price of this issuance is set at HK$26.66 per share, with a total of 26.632 million shares offered. The total funds raised amount to approximately HK$710 million. The Hong Kong public offering recorded an overwhelming subscription, with an oversubscription ratio of approximately 7,569 times, demonstrating the market's strong recognition of Deepexi Technology’s leading position in the enterprise large model AI application solution sector and its future growth potential. The company plans to allocate the raised funds to the following strategic directions: approximately 40% for enhancing R&D capabilities; approximately 30% for expansion of sales network and customer base in China; approximately 15% for overseas business expansion; approximately 5% for potential investment, mergers and acquisitions; and 10% for working capital and general corporate purposes. This funding plan will provide solid momentum for Deepexi Technology to consolidate its technological barriers and accelerate its commercialization process.Notably, as early as 2021, GTJAI co-led a USD$100 million Series B financing round for Deepexi Technology , which was completed in 2022. This early involvement demonstrated GTJAI’s strategic foresight in identifying high-growth potential in the AI sector and laid a solid foundation for subsequent collaboration in supporting Deepexi Technology’s listing in Hong Kong. In the future, GTJAI will continue to leverage its professional financial services capabilities to connect more innovative technology companies with global capital markets.  About Deepexi TechnologyDeepexi Technology is China's leading provider of enterprise large model AI application solutions. Through its FastData enterprise data intelligence solution and FastAGI enterprise AI solution, it empowers enterprises to integrate their data, decisions and operations efficiently at scale. Deepexi Technology ranked fifth in China’s enterprise large model AI application solution market in terms of revenue in 2024. Its solutions have achieved large-scale commercialization across multiple verticals, including consumer goods, manufacturing, healthcare and transportation. As of June 30, 2025, Deepexi Technology served a cumulative total of 283 enterprise customers across various industries, with multiple engagements representing 33.2% of customer base, reflecting strong customer loyalty and satisfaction.  About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月29日 - (亚太商訊) - 2025年10月28日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）作为独家保荐人、保荐人兼整体协调人、整体协调人、联席全球协调人、联席账薄管理人及联席牵头经办人，成功助力上海剑桥科技股份有限公司（"剑桥科技"，股份代号：6166. HK，603083.SH）在香港联交所主板上市。剑桥科技由此成为光模块及CPO（Co-packagedoptics，光电共封装技术）领域首家实现"A+H"双平台上市的企业。此次港股发行创下A股与港股通信设备行业有史以来最大规模IPO纪录，充分彰显国泰海通集团在跨境资本运作中高效整合资源、服务大型科技企业的综合实力。本次发行最终定价为每股68.88港元，总发售股数达6,701万股，基础发行规模46.16亿港元，超额配售权完全行使后预计总集资额将达53.08亿港元。国际配售和香港公开发售录得踊跃认购，国际配售认购倍数达16.5倍，香港公开发售认购倍数达338.7倍。截至2025年10月28日，以募资规模计，本项目为2025年前三大独家保荐港股IPO项目。在项目执行过程中，国泰君安国际凭借高效的沟通协调与执行力，助力剑桥科技在六个月内完成从递交H股上市申请到成功在港挂牌的全流程。项目团队深入挖掘和打造公司投资故事，聚焦公司在AI基础设施、光通信及光模块领域的领先地位及技术优势，开展扎实深入的市场推介工作，对接全球顶尖投资者，帮助剑桥科技引入霸菱、摩根士丹利、HCEP、Arc Avenue、奇点资产、Weiss、Cithara、3W、Schonfeld、无极资本、Alpine、Dymon Asia、博裕、Martis、泰康人寿、工银理财共计16名顶尖基石投资者，基石投资占比48.89%，涵盖顶尖外资长线基金、知名外资多策略基金、中资长线基金，并于国际配售中进一步引入众多全球顶尖长线基金和主权基金订单，既展现了国泰君安国际领先的全球投资者覆盖能力，也凸显了全球顶尖资本对剑桥科技长期发展前景的信心。关于剑桥科技剑桥科技是全球领先的AI基础设施提供商，专注于光模块、宽带和无线等联接与传输设备的设计、研发、制造与销售，其产品广泛应用于算力集群内部、算力集群之间、算力集群与用户之间以及用户端内部大量算力和数据的高效连接，下游客户包括全球领先的人工智能数据中心、电信运营商、ICT设备提供商、多系统运营商及物联网解决方案提供商。公司在中国、美国及日本设立了六大研发中心，通过自有工厂和Co-location合作模式，公司在中国、美国、欧盟及马来西亚设立了七大生产基地。凭借公司在行业内的强势地位及广泛的全球布局，公司将持续受益于人工智能高速发展带来的巨大增长机遇。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) – October 28, As the sole sponsor, sponsor-overall coordinator, overall coordinator, joint global coordinator, joint bookrunner and joint lead manager, Guotai Junan International Holdings Limited (“GTJAI” or “the Company”, stock code: 1788.HK), a company of Guotai Haitong Group, facilitated the successful listing of  CIG SHANGHAI CO., LTD. (“CIG”, stock code: 6166.HK，603083.SH) on the main board of the Hong Kong Stock Exchange. This listing establishes CIG as the first photonics and CPO (Co-packaged Optics) company with dual listings in both the A-share and H-share markets. Marking the largest IPO ever in the telecommunications equipment sector across these markets, the offering fully demonstrates Guotai Haitong Group's comprehensive capabilities in resource integration and serving large technology enterprises through cross-border capital operations. The final offering price for this issuance is set at HK$68.88 per share, with a total of 67.01 million shares offered, representing a base offering size of HK$4.616 billion. Upon full exercise of the over-allotment option, the total proceeds are expected to reach HK$5.308 billion. The offering attracted strong investor interest, with the international placement oversubscribed by approximately 16.5 times and the Hong Kong public offering oversubscribed by approximately 338.7 times. As of October 28, 2025, this transaction ranks among the top three Hong Kong IPO projects by fundraising size led by a sole sponsor in 2025. Throughout the project execution, GTJAI leveraged its efficient communication, coordination and execution capabilities to assist CIG in completing the entire process—from submitting its H-share listing application to successfully listing in Hong Kong—within six months.The project team conducted in-depth research and crafted the company's investment narrative, highlighting its leading position and technological advantages in AI infrastructure, optical communication and photonics. Through robust and thorough market outreach, they connected with the world's top investors and assisted CIG in engaging a total of 16 top-tier cornerstone investors, including Barings, Morgan Stanley, HCEP, Arc Avenue, CloudAlpha Capital, Weiss, Cithara, 3W, Schonfeld, Infini Capital, Alpine, Dymon Asia, Boyu, Martis, Taikang Life and ICBC WM with cornerstone investments accounting for 48.89% of the total. These investors encompass premier foreign long-term funds, renowned foreign multi-strategy funds and Chinese long-term funds. International placement further secured orders from numerous top global long-term funds and sovereign wealth funds. This achievement not only demonstrates GTJAI’s leading global investor coverage capabilities but also underscores the confidence of world-class capital in CIG’s long-term development prospects. About CIGCIG is a globally leading AI infrastructure provider specializing in the design, R&D, manufacturing and sales of connectivity and transmission equipment such as photonics, broadband and wireless solutions. Its products are extensively deployed for efficient connectivity within computing clusters, between clusters, between clusters and users, and within user endpoints to manage massive computing power and data flows. Its downstream clients include world-leading AI data centres, telecom operators, ICT equipment providers, multiple system operators and internet-of-things solutions providers. The company has established six major R&D centres in China, the United States and Japan. Through its own manufacturing facilities and Co-location partnerships, it has set up seven production bases in China, the United States, the European Union and Malaysia. Leveraging its strong industry position and extensive global footprint, the company will continue to benefit from the tremendous growth opportunities presented by the rapid advancement of artificial intelligence.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 第20届国际环保博览今天起一连四天于亚洲国际博览馆举行，吸引来自13个国家及地区、约340家展商参与- 博览多元活动和产品科技响应施政报告，涵盖循环经济及废物处理、绿色及智慧出行、以及ESG相关服务三大领域- 大会将于明天举行「环保企业"走出去" 经验交流会」，多位一带一路国家政府官员及半官方机构代表分享开拓当地市场策略，助环保企业拓阔国际网络香港, 2025年10月28日 - (亚太商訊) - 由香港贸易发展局（香港贸发局）、法兰克福展览（香港）有限公司合办，并由香港特别行政区政府环境及生态局协办的第20届国际环保博览，今日起一连四天（10月28至31日）于亚洲国际博览馆举行，吸引来自13个国家及地区、约340家展商，带来各式创新环保科技产品、ESG及可持续发展方案，为业界打造优质的商贸平台。博览最后一天（即10月31日）为公众日，免费开放予公众人士入场，鼓励市民参与环保活动，实践绿色生活。中华人民共和国生态环境部副部长于会文、工业和信息化部节能与综合利用司副司长丁志军、香港特别行政区环境及生态局局长谢展寰、香港贸发局总裁张淑芬、法兰克福展览（香港）有限公司执行董事李庆新等，今日出席国际环保博览开幕典礼。香港贸发局总裁张淑芬表示：「今年国际环保博览迎来第20届的重要里程碑，不仅展示我们对可持续发展的承诺，也凸显我们持续推动绿色创新及与绿色业界合作生态圈的使命。今年博览以『绿色科技 引领零碳未来』为主题，为绿色产业提供宝贵的交流机会，再次匯聚业界领袖共同为永续的未来铺路，这亦与香港特区政府的净零排放目标互相配合。」环境及生态局局长谢展寰于开幕典礼致辞时表示：「在全球迈向可持续发展的过程中，香港发挥『超级联繫人』的角色。凭藉我们作为粤港澳大湾区内国际都会的独特地位，以及担当中国内地对接世界的桥樑，香港匯聚人才、科技与资本，能促进合作和扩大绿色创新。」环球展商云集 展示创新环保科技今年博览共有17个展团，本地方面，环境运动委员会首次组织展馆，带来22家本地绿色初创，还有环境及生态局等11个政府单位组成的展区等。中国内地包括广东、广州、深圳、广西、湖南、上海、内蒙古亦组团参展。由『一带一路』国际科学组织联盟(ANSO)及11家内地企业组成的ANSO环境科技产业联盟展馆更首次亮相，展示与水资源和大气环境有关的技术，藉着参展为联盟企业开拓海外市场奠定基础。海外展团方面，今年新增韩国及意大利展团，挪威、荷兰及加拿大展团亦载誉归来。大会积极建构平台协助港商及内地企业「出海」，吸引来自日本、泰国、印尼、马来西亚、新加坡、越南、匈牙利及波兰的买家组团参观及採购。至于明天举行的「环保企业"走出去"经验交流会」，特区政府邀请多位一带一路国家政府官员及半官方机构代表分享开拓当地市场策略。大会亦与环境及生态局合作，广邀内地、东盟及「一带一路」国家政府的服务供应商，亲临博览採购环保科技及产品。三大领域响应施政报告 智能与环保兼具环保成为近年政策焦点之一，中国内地近期发布《关于推进绿色低碳转型加强全国碳市场建设的意见》，成为指引「十五五」时期中国碳市场深化改革的纲领性文件。今年政府亦提出建设绿色低碳生活环境，致力加速绿色技术应用等。配合产业发展，博览匯聚多元绿色科技，展示循环经济及废物处理、绿色及智慧出行、以及ESG相关服务三大领域最新成果。在循环经济及废物处理展区，绿色人工智能科技（展位编号：3-D38）展示AI 智能分类垃圾桶，装置可透过即时AI废物识别，提供互动学习体验，教授正确回收方法。另外，绿色动力环保集团（展位编号：3-E30）带来再生能源发电厂项目，助力城市永续发展。于绿色及智慧出行领域，内地装备制造业龙头三一集团港澳地区子公司三一腾飞机械（展位编号：6-C26）则带来三一锂能电源车，可同时为两台电动卡车充电。 内地洁净能源设备制造商中集安瑞科控股有限公司（展位编号：3-F14），展示用于运输和储存氢能及绿色甲醇的创新技术方案。博览亦带来ESG相关服务，Llewellyn and Partners Company（展位编号：6-D14）带来为建筑业而设的专利AI 综合管理平台AutoTwin，协助减少建筑运营成本、时间及碳排放。加拿大科技公司XSIM AI Canada Inc.（展位编号：6-C23）则透过AI驱动的系统，为污水处理厂及工业设施减少高达30%的停机时间、营运成本及碳排放。学研机构与初创亦不容忽视，除香港中文大学（展位编号：3-G24）亦再度参与外，岭南大学（展位编号：6-A25）和香港理工大学晋江技术创新研究院（展位编号：6-A23）今年首次参展。香港科技园公司（展位编号：3-F20）带来初创afterNATURE（展位编号：3-F20），展出六角形深水盆，用以维持海岸线的生态与海洋生物多样性而设。另一家园区初创远见筑（展位编号：3-F20）则展示AtmosBrick 及于博览全球首发AtmosTile「负碳」绿建材，将二氧化碳转化为高性能建材，大幅降低碳足迹。业界领袖聚首「亚洲环保会议」建造业与交通运输业成焦点博览焦点活动「亚洲环保会议」今天举行政府环节，中华人民共和国工业和信息化部节能与综合利用司副司长丁志军在会上分享国家最新环保政策及动向，缅甸、斯里兰卡、菲律宾等多个一带一路国家的政府官员亦会讲解当地最新绿色政策及项目；同日另一环节则以「循环经济：革新与创新解决方案」为主题，由商界环保协会带领多位专家，探讨如何在商业运营上应用循环经济概念，会议中亦会首度推出《香港循环建筑环境指南》，为建造业带来最新绿色指引。博览第三日（10月30日）的会议主题围绕「构建可持续未来：迈向净零建筑环境」及「绿色智慧出行 - 引领未来出行潮流」，邀请多位业界领袖及专家分享真知灼见，包括机电工程署副署长陈柏祥、香港生产力促进局先进能源及智慧交通中心技术及商品化主管莫天德博士等，分别讨论建筑业及交通运输行业如何透过有效合作，构建可持续发展城市。其他精彩活动包括博览首日（10月28日）的「香港工业总会．Q唛低碳餐厅大奖」颁奖典礼；于第二日（10月29日）举行的第六届氢能经济论坛，香港特区政府环境及生态局副局长黄淑娴届时会带来主题演讲，而中国城市燃气氢能发展创新联盟副理事长王子缘将分享粤港澳大湾区氢能机遇与挑战。博览同时设有不同研讨会，包括为推动绿色初创企业发展而设的「初创．动起来」，邀请来自不同环保领域的初创代表进行分享。博览于最后一天（10月31日）为公众日，免费开放予市民入场，鼓励市民参与环保活动。当日特设一系列的环保生活讲座、工作坊和活动，当中包括近期热话极端天气，由香港天文台总学术主任陈敏仪进行分享；海洋公园亦会分享「逆濒行动 Mission R」保护濒危野生动物与其栖息环境的相关资讯。市民亦可参与不同环保工作坊，同场亦设有绿色市集供市民选购环保产品。其他同期活动香港国际户外及科技照明博览在10月28至31日同于亚博馆举行，展示各种商业和工业用的室外及专业技术照明解决方案，而香港国际秋季灯饰展（秋灯展）已于昨天起一连四天（10月27日至30日）在香港会议展览中心举行。大会已安排免费穿梭巴士服务，往来展场及各主要酒店与交通交匯点。详情请参阅以下网页︰https://www.hktdc.com/event/ecoexpoasia/sc/travel-to-fairground-awe图片下载：https://bit.ly/48MjH8F由香港贸发局及法兰克福展览（香港）有限公司合办的第20届国际环保博览揭幕，博览一连四天（10月28至31日）假亚洲国际博览馆举行，吸引约340家展商参与。图为中华人民共和国生态环境部副部长于会文、工业和信息化部节能与综合利用司副司长丁志军、香港特别行政区环境及生态局局长谢展寰、香港贸发局总裁张淑芬及一众嘉宾，出席国际环保博览开幕典礼盛况。中华人民共和国生态环境部副部长于会文（左三）、香港特别行政区环境及生态局局长谢展寰（右三）、香港贸发局总裁张淑芬（左二）及一众嘉宾到场参观。香港特区政府邀请多位一带一路国家及地区的政府官员及半官方机构代表出席第20届国际环保博览，包括柬埔寨、缅甸及斯里兰卡等。今年博览共有17个展团参展，当中包括环境运动委员会首次组织展馆，带来22家本地初创。海外展团方面，今年新增韩国展团，阵容鼎盛。绿色及智慧出行属今年新增领域，聚焦于各种崭新的绿色运输方案及产品。业界新血亦不容忽视，学研机构与初创带来创新绿色方案。「亚洲环保会议」邀请来自世界各地的官员、行业领袖和专家，就不同议题分享真知灼见。网页国际环保博览：www.ecoexpoasia.com/sc传媒查询请联络香港贸发局传讯及公共事务部：苏显博电话：(852) 2584 4049电邮：stanley.hp.so@hktdc.org刘茸电话：(852) 2584 4472电邮：clayton.y.lauw@hktdc.org香港贸发局新闻中心︰http://mediaroom.hktdc.com/sc香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企业)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。法兰克福展览集团简介法兰克福展览集团是全球最大的拥有自主展览场地的展会主办机构之一，其业务覆盖展览会、会议及活动，在全球29个地区聘用约2,160名员工，业务版图遍及世界各地。2022年营业额约4.54亿欧元，集团与众多行业领域建立了丰富的全球商贸网络并保持紧密联繫，在展览活动、场地和服务业务领域，高效满足客户的商业利益和全方位需求。法兰克福展览集团核心优势在于遍布世界各地庞大、紧密的国际行销网络，覆盖全球约180个国家。多元化的服务呈现在活动现场及网络平台的各个环节，确保遍布世界各地的客户在策划、组织及进行活动时，能持续享受到高品质及灵活性。我们正在通过新的商业模式积极拓展数字化服务范畴，可提供的服务类型包括租用展览场地、展会搭建、市场推广、人力安排以及餐饮供应。作为核心战略体系之一，集团积极实践可持续化经营理念，在生态、经济利益、社会责任和多样性之间达成有益的平衡。有关集团可持续发展进一步资料，请浏览网页：www.messefrankfurt.com/sustainability。集团总部位于德国法兰克福市，由该市和黑森州政府分别控股60%和40%。有关公司进一步资料，请浏览网页：www.messefrankfurt.com.hk。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

喬治敦，肯塔基, 2025年10月28日 - (亚太商讯 via SeaPRwire.com) - 作为一家专注于高频交易（HFT）的自营交易公司，Octo Horizon 正在推动下一代交易基础设施的发展——在这里，卓越的工程能力、低延迟系统和高性能软件共同驱动可衡量的成果。octo-horizon-high-performance-infrastructure该公司将交易视为一项大型工程挑战，专注于优化系统性能、网络吞吐量和执行速度。Octo Horizon 的工程师们致力于使用 C++、并发设计和确定性架构开发最前沿的基础设施，以确保在高要求的环境下实现可靠、可预测的运行。内核旁路网络、无锁数据结构以及实时分析等技术工具被广泛应用于降低延迟、提升效率。工程为核心工程精确性是 Octo Horizon 核心理念的基础。团队在高性能软件、分布式系统和实时数据处理领域密切合作，对每一层——从网络驱动到执行逻辑——进行精细调校，以实现最佳性能。持续的基准测试、性能分析和剖析被嵌入开发流程中，以确保系统结果稳定且可预测。开发人员还参与严格的测试体系，包括单元测试、集成测试和压力测试，以验证系统在高负载条件下的可靠性。监控、日志记录和性能可视化等工具被整合进工作流程，使工程师能够在纳秒级别识别瓶颈并优化系统吞吐量。技术理念对 Octo Horizon 来说，交易是一项技术性的探索。公司强调简洁性、可复现性和系统级优化，致力于解决低延迟网络、异步处理以及事件驱动架构中的复杂问题。团队设计模块化、可维护的系统，使其能够高效扩展并适应不断变化的市场环境，同时尽量减少资源开销。实时决策与确定性行为是核心原则。每个系统组件都会从延迟、并发性和稳定性等维度进行评估。这种方法确保公司技术体系的可靠性、韧性，以及支持高吞吐量电子化市场的能力。文化与协作Octo Horizon 致力于营造协作与创新并重的工作环境。工程师、系统开发人员和量化研究员跨学科紧密合作，交流思想、审查设计并优化实现。公司高度重视自主性、技术好奇心和细节专注度，形成一种以个人专业能力驱动可衡量成果与持续改进的文化。工程师与研究员的机遇Octo Horizon 正在扩大其技术与研究团队，现正积极招聘以下职位：量化研究员软件工程师DevOps 工程师我们诚邀热衷于高性能计算、分布式系统和低延迟软件开发的优秀人才加入。公司提供一个鼓励技术精进、探索精神与创新思维的环境，让您有机会参与解决具有挑战性的实际问题，并见证切实成果。欲了解更多信息并申请，请访问 https://www.octo-horizon.com/jobs 联系信息Media Octo Horizonservice@octo-horizon.com来源: Octo Horizon Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GEORGE TOWN, KY, Oct 28, 2025 - (ACN Newswire via SeaPRwire.com) - Octo Horizon, a proprietary trading firm specializing in high-frequency trading (HFT), is advancing the next generation of trading infrastructure - where engineering excellence, low-latency systems, and high-performance software drive measurable results.octo-horizon-high-performance-infrastructureEngineering-driven infrastructure at Octo Horizon powers next-generation trading technology.The firm approaches trading as a large-scale engineering challenge, focusing on optimizing system performance, network throughput, and execution speed. Engineers at Octo Horizon work on cutting-edge infrastructure using C++, concurrency design, and deterministic architectures to ensure reliable, predictable operation under demanding conditions. Kernel-bypass networking, lock-free data structures, and real-time analytics are among the tools applied to reduce latency and maximize efficiency.Engineering at the CoreEngineering precision is central to Octo Horizon's philosophy. Teams collaborate on high-performance software, distributed systems, and real-time data processing, tuning every layer - from network drivers to execution logic - to achieve optimal performance. Continuous benchmarking, profiling, and performance analysis are embedded in the development workflow to maintain stable, predictable results.Developers also engage in rigorous testing frameworks, including unit, integration, and stress testing, to validate system reliability under peak load conditions. Tooling for monitoring, logging, and performance visualization is integrated into the workflow, allowing engineers to identify bottlenecks and optimize system throughput at the nanosecond scale.Technology PhilosophyFor Octo Horizon, trading is a technical pursuit. The firm emphasizes simplicity, reproducibility, and system-level optimization, solving complex problems in low-latency networking, asynchronous processing, and event-driven architectures. Teams design modular, maintainable systems that scale efficiently and adapt to evolving market conditions, while minimizing resource overhead.Real-time decision-making and deterministic behavior are central, with every system component evaluated for latency, concurrency, and stability. This approach ensures that the firm's technology remains reliable, resilient, and capable of supporting high-throughput electronic markets.Culture and CollaborationOcto Horizon fosters a collaborative and innovation-driven environment. Engineers, systems developers, and quantitative researchers work closely across disciplines to exchange ideas, review designs, and refine implementations. Autonomy, technical curiosity, and attention to detail are highly valued, creating a culture where individual expertise drives measurable impact and continuous improvement.Opportunities for Engineers and ResearchersOcto Horizon is expanding its technology and research teams and is actively hiring for the following positions:Quantitative ResearcherSoftware EngineerDevOps EngineerCandidates passionate about high-performance computing, distributed systems, and low-latency software are encouraged to apply. The firm offers an environment that rewards technical mastery, curiosity, and innovation - with the opportunity to work on challenging real-world problems with visible results.For more information and to apply, visit https://www.octo-horizon.com/jobsContact InformationMedia Octo Horizonservice@octo-horizon.comSOURCE: Octo Horizon Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - October 28, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that Beijer Ref has agreed to offer the Company's proprietary THERMAL-XR® ENHANCE heat transfer coating as an optional coating solution on Beijer Ref and Kirby branded refrigeration evaporator coils, including the Beijer Patton and Kirby Guardian lines as seen in Figure 1, across all of Beijer Ref's and Kirby's approximately 73 wholesale locations in Australia starting from 17 November 2025. Beijer Ref customers electing to have the optional coating solution applied to their Beijer Ref or Kirby refrigeration evaporator coils will contract directly with Beijer Ref, who will enter into a bilateral agreement with the Company, subject to GMG's standard terms and conditions. This collaboration marks a significant milestone in GMG's commercialization of its innovative coating products for energy efficiency and corrosion resistance in the HVAC-R industry.Figure 1: Beijer Patton Evaporator Coil and Kirby Guardian Evaporator CoilTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/272201_gmg_figure1_550.jpgWhile the collaboration is for an indeterminate period, the Company anticipates that as the advantages of THERMAL-XR® ENHANCE are experienced by customers electing to have the coating applied, the benefits to both Beijer Ref and the Company will support a long-term arrangement. However, at present either party may terminate the collaboration at any time.Beijer Ref is one of the world's largest global refrigeration and HVAC wholesalers, headquartered in Malmö, Sweden, with operations spanning more than 40 countries and over 500 branches worldwide, 6,000 employees and 200,000 customers. In Australia, Beijer Ref Group distributes through Kirby, Beijer Ref Australia, SCM REF Australia, and ACD Trade, providing air conditioning and refrigeration equipment, components, and engineering solutions. The company serves diverse sectors such as supermarkets, cold storage, and industrial refrigeration, combining expertise with local manufacturing and distribution capabilities.GMG's THERMAL-XR® ENHANCE coating utilizes the Company's unique graphene-based formulation to improve the thermal performance and longevity of heat exchange surfaces. The application of this coating to Beijer Patton and Kirby Guardian evaporator coils is expected to enhance corrosion resistance, cooling efficiency, reduce energy consumption and provide sustainability benefits across diverse cooling environments. This initiative extends the availability of GMG's product through Beijer Ref's extensive distribution network while offering Australian customers improved system performance and energy/emission reduction pathways.GMG plans to utilize a network of trained and approved HVAC contractors to apply its THERMAL-XR® ENHANCE coating on refrigeration and air-conditioning coils for this roll out for coating Beijer Ref products starting in the capital cities of mainland Australia. Each participating contractor will undergo GMG certification in the GMG SPRAY ACADEMY to ensure they are proficient in the coating's three-stage process: surface cleaning and preparation, graphene-based coating application, and post-application inspection and maintenance verification. This ensures consistent quality, adherence to safety protocols, and correct use of GMG's proprietary application methods.​​These certified contractors will deliver coating services on-site or at pre-approved GMG spray coating plants nationally, enabling GMG to scale deployment seamlessly through both direct and distributor channels, particularly in collaboration with Beijer Ref and Kirby stores. By drawing on established HVAC service professionals, the Company ensures local availability, rapid turnaround for installations, and full compliance with the quality standards required for quality assurance.​This contractor program forms part of GMG's strategic commercialization model, where trained technicians act as frontline partners in the installation of graphene-enhanced coatings for end users. The approach maximizes accessibility, maintains warranty integrity, and strengthens GMG's reputation for technical excellence and customer support across Australia's HVAC-R market.GMG's Chief Executive Officer, Craig Nicol, commented: "We are proud to see THERMAL-XR® ENHANCE incorporated into Beijer Ref's and Kirby's product offerings in Australia as an option for their leading HVAC-R products. This partnership demonstrates the growing recognition of graphene-enhanced materials as a viable route to corrosion resistance and greater efficiency in conventional HVAC-R systems. The Company continues to expand its market reach globally through strategic channel partners and remains committed to advancing environmentally responsible technologies through graphene innovation."GMG's Chairman and Non-Executive Director, Jack Perkowski, commented "Congrats to the team – great to see this next step in the roll out of GMG's global leading energy saving products."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the offering of THERMAL-XR® ENHANCE heat transfer coating on Beijer Ref and Kirby branded refrigeration evaporator coils, THERMAL-XR® ENHANCE's ability to enhance corrosion resistance, cooling efficiency, reduce energy consumption, and provide sustainability benefits across diverse cooling environments, improve system performance and energy/emission reduction pathways, the intention to utilize a network of trained and approved HVAC contractors to apply its THERMAL-XR® ENHANCE coating, the proficiency of contractors in the application of THERMAL-XR® ENHANCE, the delivery of coating services on-site or at pre-approved GMG spray coating plants, the Company's ability to scale deployment seamlessly, the Company's ability to ensure local availability, rapid turnaround for installations, and full compliance with the quality standards required for quality assurance, the strategic commercialization model's ability to maximize accessibility, maintain warranty integrity, and strengthen GMG's reputation for technical excellence and customer support across Australia's HVAC-R market, the growth in recognition of graphene-enhanced materials as a viable route to corrosion resistance and greater efficiency in conventional HVAC-R systems, the Company's continued expansion of its market reach globally through strategic channel partners and the Company's commitment to advancing environmentally responsible technologies through graphene innovation.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, that GMG will be able to take orders and deliveries to meet distributor demand around the worldwide. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, that products may not be available for sales or delivery to meet customers' expectations.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272201 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- The 20th edition of Eco Expo Asia opens today for four days at AsiaWorld-Expo, gathering some 340 exhibitors from 13 countries and regions- The Expo features diverse activities and product technologies in response to the Policy Address, covering three key areas – Circular Economy and Waste Management, Green & Smart Mobility and ESG-related Services- The ‘Experience Sharing Forum on Promoting Environmental Business in Overseas Markets’ will be held tomorrow. Government officials and representatives of quasi-governmental organisations from Belt and Road countries will share strategies for local market development, to help green companies expand their international networksHONG KONG, Oct 28, 2025 - (ACN Newswire via SeaPRwire.com) – The 20th Eco Expo Asia, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd and co-organised by the Environment and Ecology Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR), opened at AsiaWorld-Expo today and runs until 31 October. Some 340 exhibitors from 13 countries and regions are showcasing innovative green technologies and products, as well as ESG and sustainable solutions. The last day of the Expo, 31 October, will open to the public for free, to encourage sustainable living practices.Yu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People’s Republic of China; Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China; Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government; HKTDC Executive Director Sophia Chong; and Richard Li, Executive Director of Messe Frankfurt (HK) Ltd, attended Eco Expo’s opening ceremony today.HKTDC Executive Director Sophia Chong said: “This year, we celebrate a significant milestone of the Expo - its 20th edition. This not only marks our commitment to sustainability but also underscores our ongoing mission to develop the ecosystem for driving innovation and collaboration to support the green agenda. Under the theme ‘Green Innovations for Carbon Neutrality’, Eco Expo Asia provides invaluable opportunities for the green industry. This year, once again, we are bringing together leading players from the eco sector to pave the way for a more sustainable future, in alignment with the Hong Kong SAR Government’s net zero goals.”Speaking at the opening ceremony, the Secretary for Environment and Ecology, Tse Chin-wan, said, "In the global journey towards sustainability, Hong Kong serves as a ‘super connector’. With our unique position as an international city within the Guangdong-Hong Kong Macao Greater Bay Area and a bridge between Chinese Mainland and the world, Hong Kong brings together talent, technology, and capital to foster collaboration and scale up green innovation.Global exhibitors gather to showcase innovative environmental technologiesThis year’s Expo brings together 17 pavilions. For the first time, the Environmental Campaign Committee is hosting a pavilion, presenting 22 local green start-ups, alongside a joint government pavilion featuring 11 bureaux and departments, including the Environment and Ecology Bureau. Chinese Mainland delegations from Guangdong, including Guangzhou and Shenzhen, Guangxi, Hunan, Inner Mongolia and Shanghai are also joining the Expo. The ANSO Environmental Technology Industry Alliance, led by the Alliance of National and International Science Organizations for the Belt and Road Regions (ANSO), is making its debut, together with 11 mainland enterprises, showcasing technologies related to water resources and the atmospheric environment, and laying the foundation for future expansion overseas. New overseas pavilions include Italy and South Korea, while Canada, the Netherlands and Norway are returning this year.The Expo is also actively building a platform to support Hong Kong and mainland enterprises to go global and explore new opportunities in green trade, attracting buyers from Japan, Thailand, Indonesia, Malaysia, Singapore, Vietnam, Hungary and Poland to visit and source at the event. For tomorrow’s ‘Experience Sharing Forum on Promoting Environmental Business in Overseas Markets’, the Hong Kong SAR Government has invited government officials and representatives from quasi-governmental organisations from Belt and Road countries to share strategies to develop local markets. In collaboration with the Environment and Ecology Bureau, the Expo extends invitations to government service providers from the Chinese Mainland, as well as from ASEAN and Belt and Road countries, to visit and source green technologies and products.Three major green and smart areas supporting the Policy AddressEnvironmental protection has become a key policy focus in recent years. The Chinese Government recently released guidelines on advancing low-carbon transition and strengthening the development of China’s carbon trading market. This year’s Policy Address highlighted new directions in green policy in Hong Kong, including fostering green and low-carbon living environments, and expediting the application of green technologies. In line with industry development, the Expo brings together a diverse range of green tech, showcasing the latest achievements in Circular Economy and Waste Management, Green & Smart Mobility and ESG-related Services.In Circular Economy and Waste Management, Green AI Technology Limited (Booth No. 3-D38) displays its AI-powered smart sorting bin with real-time waste identification, demonstrating good recycling methods through interactive learning. Dynagreen Environmental Protection Group Co., Ltd (Booth No. 3-E30) showcases its comprehensive waste treatment project, contributing to sustainable urban development.In Green & Smart Mobility, SANY Turbo Fly Machine Limited (Booth No. 6-C26) from Hong Kong and Macao, a subsidiary of SANY Group, a leading equipment manufacturing company in the Chinese Mainland, brings its SANY Mobile Charging Power Station, which can charge two electric trucks simultaneously. CIMC Enric Investment Holding (Shenzhen) Co., Ltd. (Booth No. 3-F14), a leading manufacturer of advanced clean energy equipment, showcases innovative hydrogen and green methanol technology solutions for transportation and storage.The Expo also showcases ESG-related services. Llewellyn and Partners Company Limited (Booth No. 6-D14) displays AutoTwin, a patented AI-powered integrated management platform for the construction industry, which helps reduce building operating costs, time and carbon emissions.  XSIM AI Canada Inc.,(Booth No. 6-C23), a Canadian technology company, empowers wastewater and industrial facilities with its AI-driven system to reduce downtime and lower operational costs, while cutting carbon emissions by up to 30% .Research institutions and start-ups also play a significant role in the Expo. In addition to the return of The Chinese University of Hong Kong (Booth No. 3-G24), Lingnan University (Booth No. 6-A25) and the Hong Kong Polytechnic University Jinjiang Technology and Innovation Research Institute (Booth No. 6-A23) are joining for the first time this year. The Hong Kong Science and Technology Parks Corporation (Booth No. 3-F20) presents start-up afterNATURE (Booth No. 3-F20), which is showcasing its Deep Hexagonal Basin product. This innovation creates habitats for marine life on its surface, helping to preserve coastal biodiversity. Another start-up, Formwork IO (Booth No. 3-F20), exhibits AtmosBrick and is globally debuting AtmosTile at the Expo. These ‘carbon-negative’ building materials are designed to help reduce carbon emissions.Eco Asia Conference brings together industry leaders, focusing on construction and transportation sectorsEco Expo’s highlight event, Eco Asia Conference, began today with the Government Session. Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China, shared the country’s latest environmental policies and trends. Officials from Myanmar, Sri Lanka, the Philippines and other Belt and Road countries also elaborated on their latest green policies and projects. Another session, ‘Revolutionising with Circular Economy: From Waste to Innovative Solutions’, featured experts led by the Business Environment Council, who explored the application of circular economy concepts in business operations. The Hong Kong Circular Built Environment Guidebook is also making its debut at the Conference, providing the latest green guidelines for the construction industry.On the third day of the Expo, on 30 October, the Conference will have two main themes: ‘Building a Sustainable Future: Gearing Towards a Net-Zero Built Environment’ and ‘Green & Smart Mobility – Envisioning the Future of Transportation’. Industry leaders and experts, including Pak-cheung Chan, Deputy Director, Electrical and Mechanical Services Department, Hong Kong SAR Government, and Dr Rick Mo, Head of the Centre of Advanced Power and Autonomous Systems (APAS), Hong Kong Productivity Council, will share insights and discuss how the construction and transportation industries can build sustainable cities through effective collaboration.Other exciting activities include the FHKI Q-Mark Low Carbon Restaurant Award 2025 on 28 October, the first day of the Expo. The 6th Hydrogen Economy Forum will be held on the second day of the Expo, on 29 October. Diane Wong, JP, Under Secretary for Environment and Ecology, Hong Kong SAR Government will deliver the keynote address, while Dr Wang Ziyuan, Vice President, China Hydrogen Development and Innovation Alliance for Urban Gas will share insights on the opportunities and challenges of hydrogen energy in the Guangdong-Hong Kong-Macao Greater Bay Area. The Expo also features various seminars, including ‘Startup Edge’, which promotes the development of green start-ups, featuring presentations by start-up representatives from various environmental fields.On 31 October, Eco Expo will open to the public free of charge, to encourage public participation in environmental initiatives through a series of talks, workshops and activities. These include a seminar on the recent hot topic of extreme weather by Man Yee Chan, Chief Experimental Officer, Hong Kong Observatory, and a presentation by Ocean Park on Mission R, an initiative to protect endangered wildlife and their habitats. The public can also participate in various environmental workshops, and purchase eco-friendly products from the Green Mart.Other concurrent eventsThe Hong Kong International Outdoor and Tech Light Expo takes place from 28 to 31 October at AsiaWorld-Expo, showcasing outdoor and professional technical lighting solutions for commercial and industrial use; while the Hong Kong International Lighting Fair (Autumn Edition) opened yesterday and will run until 30 October at the Hong Kong Convention and Exhibition Centre. Free shuttle bus services are offered between these venues and other locations in the city throughout the fair period. Please refer to the following page for details:https://www.hktdc.com/event/ecoexpoasia/en/travel-to-fairground-awePhoto download: https://bit.ly/48MjH8FThe 20th Eco Expo Asia, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd, opened at AsiaWorld-Expo today and runs until 31 October, attracting some 340 exhibitors. Yu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People's Republic of China, Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China; Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government; Sophia Chong, HKTDC Executive Director, and other honourable guests attended the opening ceremonyYu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People's Republic of China (third left), Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government (third right), Sophia Chong, HKTDC Executive Director (second left), and other honourable guests visited the ExpoThe Hong Kong SAR Government has invited government officials and representatives of quasi-governmental organisations from Belt and Road countries and regions, including Cambodia, Myanmar and Sri Lanka, to attend the 20th Eco Expo AsiaThis year’s Expo brings together 17 pavilions. For the first time, the Environmental Campaign Committee is hosting a pavilion, presenting 22 local green start-upsKorea is a new pavilion from overseas, with a strong lineupGreen and Smart Mobility is a new zone that has been added this year, focusing on green transport solutions and productsIndustry newcomers, such as research institutions and start-ups, bring innovative green solutionsThe Eco Asia Conference gathers global officials, industry leaders and experts to exchange insights on environmental issuesWebsiteEco Expo Asia: www.ecoexpoasia.comMedia enquiriesPlease contact the HKTDC’s Communications and Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton Lauw    Tel: (852) 2584 4472  Email: clayton.y.lauw@hktdc.orgThe HKTDC’s Media Room: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Messe FrankfurtThe Messe Frankfurt Group is one of the world’s leading trade fair, congress and event organisers with its own exhibition grounds. With a workforce of some 2,160 people at its headquarters in Frankfurt am Main and in 28 subsidiaries, it organises events around the world. Group sales in financial year 2022 were around €454 million. We serve our customers’ business interests efficiently within the framework of our Fairs & Events, Locations and Services business fields. One of Messe Frankfurt’s key strengths is its powerful and closely knit global sales network, which covers around 180 countries in all regions of the world. Our comprehensive range of services – both onsite and online – ensures that customers worldwide enjoy consistently high quality and flexibility when planning, organising and running their events. We are using our digital expertise to develop new business models. The wide range of services includes renting exhibition grounds, trade fair construction and marketing, personnel and food services. Sustainability is a central pillar of our corporate strategy. Here, we strike a healthy balance between ecological and economic interests, social responsibility and diversity.For more information, please visit our website at: www.messefrankfurt.com/sustainability. With its headquarters in Frankfurt am Main, the company is owned by the City of Frankfurt (60%) and the State of Hesse (40%). For more information, please visit our website at: www.messefrankfurt.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Rouyn-Noranda, Quebec--(ACN Newswire via SeaPRwire.com - October 28, 2025) - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to announce assay results from fifteen new drill holes completed at its 100%-owned O'Brien Gold Project ("O'Brien" or the "Project") located in the Abitibi region of Québec. The fifteen holes represent step-outs below the existing geological model and the historic O'Brien Gold Mine and are part of an ongoing 140,000-metre drill program designed to test the overall scope of gold mineralization at the Project (see Radisson news release dated October 16, 2025). All holes intersected gold mineralization in characteristic quartz-sulphide-gold veins within alteration zones, and thirteen of the holes returned intercepts with grades and thicknesses consistent with the Project's existing mineral resources.Today's results include significant intercepts in three separate step-out locations (Figures 1 & 2), each of which has significance for the potential future growth of the Project's mineral resources. These are:Between Trends #1 and #2 at 1,000 Metres Vertical DepthOB-25-371W5 intersected 10.50 grams per tonne ("g/t") gold ("Au") over 6.5 metres, including 14.90 g/t Au over 1.5 metres and including 16.95 g/t Au over 1.0 metreOB-25-371W4 intersected 11.25 g/t Au over 2.5 metres, including 17.80 g/t Au over 1.5 metresOB-25-371W6 intersected 4.51 g/t Au over 9.0 metres, including 10.70 g/t Au over 1.5 metresBeneath the Historic "O'Brien Mine West" at 1,000 Metres Vertical Depth OB-25-376W1 intersected 9.16 g/t Au over 2.5 metres, including 14.70 g/t Au over 1.1 metresOB-25-376 intersected 8.05 g/t Au over 2.50 metres, including 15.75 g/t Au over 1.0 metreBeneath the Historic "O'Brien Mine" at 1,100 Metres Vertical DepthOB-24-337W11 intersected 7.00 g/t Au over 3.0 metres, including 12.60 g/t Au over 1.5 metres, and 13.00 g/t Au over 1.50 metresMatt Manson, President & CEO, commented: "Today's drill results illustrate the extension of classic, high-grade O'Brien gold mineralization across a broad front. We are reporting the first high-grade intercepts beneath the western portion of the historic mine, with drill hole OB-25-376W1 extending mineralization 160 metres below the former mine in this area. Drill hole OB-24-337W11 demonstrates continuity of high-grade mineralization below the main stope of the historic mine. Of particular note, drill holes OB-25-371W4 to W6 returned high-grade mineralization on the western edge of the deep extension of Trend #2, close to the observed extension of Trend #1 (Figures 1&2). This suggests that the apparent gap between these two trends is a function of drill coverage rather than geology, as we have suspected. Closing this gap with new drilling is a priority. With a fully-funded 140,000-metre drill program ongoing and an increase in rigs from the current four to an eventual eight, we are casting a wide net at O'Brien and seeing consistent success."Figure 1: Longitudinal Vertical Section and Plan View of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Today's Drill Holes IllustratedTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_002full.jpgNotes on Calculation of Drill Intercepts:The O'Brien Gold Project Mineral Resource Estimate effective May 6, 2025 ("MRE") utilizes a 2.20 g/t Au bottom cut-off, a US$2,000 gold price, a minimum mining width of 1.2 metres, and a 40 g/t Au upper cap on composites. Intercepts presented in Table 1 are calculated with a 3.00 g/t Au bottom cut-off. True widths, based on depth of intercept and drill hole inclination, are estimated to be 30-80% of core length. Table 2 presents additional drill intercepts calculated with a 1.00 g/t bottom cut-off over a minimum 1.0 metre core length so as to illustrate the frequency and continuity of mineralized intervals within which high-grade gold veins at O'Brien are developed. Lithology Codes: PON-S3: Pontiac Sediments; V3-S, V3-N, V3-CEN: Basalt-South, North, Central; S1P, S3P: Conglomerate; POR-S, POR-N: Porphyry South, North; TX: Crystal Tuff; ZFLLC: Larder Lake-Cadillac Fault Zone.Figure 2: Longitudinal Vertical Section of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Deep Step-Out Drill Holes Completed and/or Published by the Company since December 2024. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_004full.jpgGold Mineralization at O'BrienGold mineralizing quartz-sulphide veins at O'Brien occur within a thin band of interlayered mafic volcanic rocks, conglomerates, and porphyritic andesitic sills of the Piché Group occurring in contact with the east-west oriented Larder Lake-Cadillac Break ("LLCB"). Gold, along with pyrite and arsenopyrite, is typically associated with shearing and a pervasive biotite alteration, and developed within multiple Piché Group lithologies and, occasionally, the hanging-wall Pontiac and footwall Cadillac meta-sedimentary rocks.As mapped at the historic O'Brien mine, and now replicated in the modern drilling, individual veins are generally narrow, ranging from several centimetres up to several metres in thickness. Multiple veins occur sub-parallel to each other, as well as sub-parallel to the Piché lithologies and the LLCB. Individual veins have well-established lateral continuity, with near-vertical, high-grade shoots developed over significant lengths. Based on the historic data available, it is clear that the former mine was "high-graded", with mining focussed on a main central stope and parallel veins identified but left undeveloped.The historic O'Brien mine produced over half a million ounces of gold from such veins and shoots at an average grade exceeding 15 g/t Au and over a vertical extent of at least 1,000 metres. Modern exploration has focussed on delineating well developed vein mineralization to the east of the historic mine, with additional high-grade shoots becoming evident in the exploration data over what has been described as a series of repeating trends ("Trend #s 0 to 5").Step-Out Drilling at O'BrienSince the end of 2024, Radisson has been pursuing a program of broad step-outs beneath the historic O'Brien Gold mine and the existing mineral resources designed to test the extent of mineralization at the Project. This drilling is accomplished with pilot holes followed by wedges and directional drilling to maximize drill efficiency. On October 16, 2025 Radisson announced the expansion of the step-out drill program to 140,000 metres employing an eventual eight drill rigs.The origin of the step-out drill program was the deep pilot hole OB-24-337, which was the first exploration drill hole located below the former mine workings since mining ended in 1957. This hole intersected 31.24 g/t Au over 8.0 metres, including 242.0 g/t Au over 1.0 metre at approximately 1,500 metres vertical depth (see Radisson news release dated December 16, 2024). With today's results, assay results from a total of 11 wedges from OB-24-337 have now been reported and up to six gold-bearing veins have been delineated over an area of approximately 250 metres (east-west) by 500 metres (vertical). Included in today's results is the eleventh wedge, OB24-337-W11, which intersected 7.00 g/t Au over 3.0 metres, including 12.60 g/t Au over 1.5 metres, and 13.00 g/t Au over 1.50 metres approximately 100 metres below the final historic mining stope (Figure 1). This serves to demonstrate the continuity of mineralization from the former mine downwards towards the cluster previously published wedges (Figures 1 & 2; see Radisson news release dated July 16, 2025). Current drilling in this area is focussed on infilling with pilot holes and wedge extensions both above and below the OB-24-337 pattern of wedge branches to test the full continuity of mineralization from the historic mine down to 2 kilometres depth.Step-out drilling with wedge branches has also confirmed high-grade mineralization 170 metres below the base of the existing mineral resources at Trend #1 and 300 metres at Trend #2. These have included pilot hole OB-24-324, which intersected 27.61 g/t Au over 6.0 metres at Trend #1 (see Radisson news release dated October 30, 2024) and OB-24-363, which intersected 8.41 g/t Au over 2.20 metres, including 14.40 g/t Au over 1.20 metres and 9.07 g/t Au over 1.80 metres, including 12.10 g/t Au over 0.90 metres at Trend #2 (see Radisson news release dated September 8, 2025). Today's results include six wedges from drill hole OB-25-371, which demonstrate strongly developed, high-grade mineralization on the western edge of the deep extension of Trend #2. These holes include OB-25-371W5, which intersected 10.50 g/t Au over 6.5 metres, including 14.90 g/t Au over 1.5 metres and including 16.95 g/t Au over 1.0 metre (Figures 1&3). The significance of these holes is that the apparent separation of Trend #1 and Trend #2 is based, in part, on a data gap caused by drill rig access restrictions and a lack of drilling (Figure 2). Targeting this gap and testing for continuity of mineralization between Trends #1 and #2, as well as at depth, is a priority of the current drill program.Today's results also include the first drill holes located below the western portion of the historic O'Brien Gold Mine, designated "O'Brien Mine West". As with the main mining area, no exploration had been conducted below O'Brien Mine West since operations ended in 1957. From pilot hole OB-25-376 and wedge branches W1 to W5, five holes returned intercepts with grades and thicknesses consistent with the Project's mineral resources, including OB-25-376W1, which intersected 9.16 g/t Au over 2.5 metres, including 14.70 g/t Au over 1.1 metres (Figure 1). This now extends gold mineralization at O'Brien Mine West 160 metres below the base of the former mine workings (Figure 4).Figure 3: Vertical Cross Section through "Trend #2" with Drill Hole Wedges OB-25-371W2 to W6To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_005full.jpg Figure 4: Vertical Cross Section through "O'Brien Mine West" with Drill Hole OB-25-376 and Wedges W1 to W5To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_006full.jpgQA/QCAll drill cores in this campaign are NQ in size. Assays were completed on sawn half-cores, with the second half kept for future reference. The samples were analyzed using standard fire assay procedures with Atomic Absorption (AA) finish at ALS Laboratory Ltd, in Val-d'Or, Quebec. Samples yielding a grade higher than 10 g/t Au were analyzed a second time by fire assay with gravimetric finish at the same laboratory. Mineralized zones containing visible gold were analyzed with metallic sieve procedure. Standard reference materials, blank samples and duplicates were inserted prior to shipment for quality assurance and quality control (QA/QC) program.Qualified Persons Disclosure of a scientific or technical nature in this news release was prepared under the supervision of Mr. Richard Nieminen, P.Geo, (QC), a geological consultant for Radisson and a Qualified Person for purposes of NI 43-101. Mr. Luke Evans, M.Sc., P.Eng., ing, of SLR Consulting (Canada) Ltd., is the Qualified Person responsible for the preparation of the MRE at O'Brien. Each of Mr. Nieminen and Mr. Evans is independent of Radisson and the O'Brien Gold Project.About Radisson MiningRadisson is a gold exploration company focused on its 100% owned O'Brien Gold Project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. A July 2025 Preliminary Economic Assessment described a low cost and high value project with an 11-year mine life and significant upside potential based on the use of existing regional infrastructure. Indicated Mineral Resources are estimated at 0.58 million ounces (2.20 million tonnes at 8.2 g/t Au), with additional Inferred Mineral Resources estimated at 0.93 million ounces (6.67 million tonnes at 4.4 g/t Au). Please see the NI 43-101 "O'Brien Gold Project Technical Report and Preliminary Economic Assessment, Québec, Canada" effective June 27, 2025, and other filings made with Canadian securities regulatory authorities available at www.sedarplus.ca for further details and assumptions relating to the O'Brien Gold Project. For more information on Radisson, visit our website at www.radissonmining.com or contact:Matt MansonPresident and CEO416.618.5885mmanson@radissonmining.comKristina PillonManager, Investor Relations604.908.1695kpillon@radissonmining.comForward-Looking StatementsThis news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements including, but are not limited to, statements with respect to the ability to execute the Company's plans relating to the O'Brien Gold Project as set out in the Preliminary Economic Assessment; the Company's ability to complete its planned exploration and development programs; the absence of adverse conditions at the O'Brien Gold Project; the absence of unforeseen operational delays; the absence of material delays in obtaining necessary permits; the price of gold remaining at levels that render the O'Brien Gold Project profitable; the Company's ability to continue raising necessary capital to finance its operations; the ability to realize on the mineral resource and mineral reserve estimates; assumptions regarding present and future business strategies; local and global geopolitical and economic conditions and the environment in which the Company operates and will operate in the future; planned and ongoing drilling; the significance of drill results; the ability to continue drilling; the impact of drilling on the definition of any resource; and the ability to incorporate new drilling in an updated technical report and resource modelling; the Company's ability to grow the O'Brien Gold Project; and the ability to convert inferred mineral resources to indicated mineral resources. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements Forward-looking information is based on estimates of management of the Company, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others; the risk that the O'Brien Gold Project will never reach the production stage (including due to a lack of financing); the Company's capital requirements and access to funding; changes in legislation, regulations and accounting standards to which the Company is subject, including environmental, health and safety standards, and the impact of such legislation, regulations and standards on the Company's activities; price volatility and availability of commodities; instability in the global financial system; the effects of high inflation, such as higher commodity prices; the risk of any future litigation against the Company; changes in project parameters and/or economic assessments as plans continue to be refined; the risk that actual costs may exceed estimated costs; geological, mining and exploration technical problems; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; risks relating to the drill results at O'Brien; the significance of drill results; and the ability of drill results to accurately predict mineralization. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Company believes that this forward-looking information is based on reasonable assumptions, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. The Company does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law. These statements speak only as of the date of this news release.Please refer to the "Risks and Uncertainties Related to Exploration" and the "Risks Related to Financing and Development" sections of the Company's Management's Discussion and Analysis dated April 29, 2025 for the year ended December 31, 2024, and the Company's Management's Discussion and Analysis dated August 27, 2025 for the three-month period ended June 30, 2025, all of which are available electronically on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272164 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 28, 2025 - (ACN Newswire via SeaPRwire.com) – On October 28, Sany Heavy Industry Co., Ltd. (6031.HK) was officially listed on the Main Board of HKEX (Hong Kong Exchanges and Clearing Limited).The listing marks a pivotal step in the company’s capital deployment and globalization strategy, coming 21 years after its July 3, 2003, listed on the Shanghai Stock Exchange (600031.SH). It also finalizes the company’s A+H dual-listing framework—a key milestone for its global expansion.On the morning of the listing, government officials, business partners, intermediaries, and Sany Heavy Industry Co., Ltd.’s management joined the ceremony at HKEX to mark the occasion. At 9:30 a.m., Mr. Xiang Wenbo, Rotating Chairman of SANY Group and Chairman of Sany Heavy Industry Co., Ltd., together with Mr. Yu Hongfu, Director of SANY Group and President of Sany Heavy Industry Co., Ltd., struck the gong at the trading hall, signaling the firm’s entry into international capital markets and the start of a new global growth phase.At the listing ceremony, Mr. Xiang Wenbo remarked: “Sany Heavy Industry Co., Ltd.’s listing in Hong Kong is both the fulfillment of opportunities and the reward for our relentless efforts. It represents not only the capital market’s recognition of SANY’s high-quality development but also a historic opportunity for Sany Heavy Industry Co., Ltd. to explore broader international financing channels and embrace a larger global market. SANY will leverage Hong Kong, which is a ‘super connector’ for international capital, continue advancing the strategy of globalization, digitalization, and decarbonization. Through innovative technology and outstanding, solid performance, we will reward investors’ trust and support, contribute SANY’s strength to the construction of the international financial center of Hong Kong, and inject SANY’s energy into global sustainable development.”For the H-share offering, Sany Heavy Industry Co., Ltd. offered approximately 632 million H-shares globally, with a 15% over-allotment option, at an offering price of HKD 21.30 per share. The IPO attracted 21 cornerstone investors, who together subscribed for US$759 million worth of shares. These cornerstone investors include Temasek, BlackRock, Infore Capital, Hillhouse, UBS Asset Management, LMR, RBC GAM, WT, Oaktree Capital, Foresight Fund, Perseverance, Greenwoods, Pinpoint, Ghisallo, Jane Street, Fenghe, Qube, Weichai Power, Dajia Insurance, Fast, and Value Partners, reflecting the strong confidence and high recognition of the international capital market in Sany Heavy Industry Co., Ltd..Since its founding, Sany Heavy Industry Co., Ltd. has transformed from a single-product, single-market player into a world-class construction machinery firm with diversified offerings, global operations, and a leading market position. This growth was driven by organic expansion, strategic acquisitions, and joint ventures.Currently, Sany Heavy Industry Co., Ltd. is advancing three core strategies: Globalization, Digitalization, and Decarbonization. Per Frost & Sullivan, it ranks 3rd globally and 1st in China for core construction machinery revenue (2020–2024). During the Track Record Period, products of the company have reached customers in over 150 countries and regions., with 2020–2024 global No.1 rankings in cumulative excavator sales and concrete machinery revenue. Overseas revenue grew at a 15.2% CAGR (2022–2024) and accounted for 57.4% of total sales in the four months ended April 30, 2025.On Digitalization, Sany Heavy Industry Co., Ltd. uses digital tech to optimize end-to-end manufacturing, operations, and services, upgrading factories to build global competitiveness. As of April 30, 2025, it is the only global construction machinery firm with two World Economic Forum (WEF)-certified Lighthouse Factories—the Beijing Piling Machinery Plant and Changsha No. 18 Plant—serving as industry benchmarks for smart manufacturing.For Decarbonization, Sany Heavy Industry Co., Ltd. is a leader in low-carbon construction machinery. It launched over 40 new energy product models in 2024, including excavators and mixers, with new energy revenue hitting RMB402.5 million—well above the global industry average contribution ratio. Its electric excavators, electric truck mixers, and electric dump trucks lead China in sales.With the H-share listing as a catalyst, Sany Heavy Industry Co., Ltd. will deepen its three strategies: expanding global client reach via Globalization, boosting competitiveness through Digitalization, and building sustainability via Decarbonization. Net proceeds from the Global Offering will fund four key areas—global sales/service network expansion, R&D enhancement, overseas manufacturing capacity growth, and working capital replenishment—to support strategy execution and create investor value.As the global market evolves, Sany Heavy Industry Co., Ltd. is poised to capitalize on global opportunities. It will continue to strengthen its position as a leading global construction machinery firm, driving growth through innovation and strategic expansion. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月28日 - (亚太商訊) - 好"市"成双，再启新程！10月28日，三一重工股份有限公司（6031.HK）在香港交易所主板正式挂牌上市。这是三一重工继2003年7月3日登陆上海证券交易所（600031.SH）后，在资本布局和全球化战略上迈出的关键一步，标志着公司成功构建"A+H"双平台上市格局。当天上午，政府领导、合作伙伴、中介机构及公司管理层齐聚香港交易所出席三一重工上市仪式，共同见证这一历史性时刻。9点30分，三一集团轮值董事长、三一重工董事长向文波与三一集团董事、三一重工总裁俞宏福一起，在交易大厅准时敲响开市锣。清脆的锣声，象征着三一重工站在新的起点，借助香港国际金融中心渠道，全面对接国际资本市场，开启全球化发展的全新篇章。向文波在上市仪式上表示："三一重工在港股上市，既是机遇带来的‘如愿以偿’，也是努力奋斗后的‘得偿所愿’。这不仅是资本市场对三一高质量发展的认可，也是三一开辟更广阔的国际融资渠道、拥抱更庞大的国际市场的历史性机遇。三一将依托香港这一跨国资本流动的‘超级枢纽’，持续推进全球化、数智化、低碳化‘三化’战略，以持续创新的技术和卓越稳健的业绩，回报投资者的信任与支持，为香港国际金融中心建设贡献三一力量，为全球可持续发展注入三一动能！"三一重工本次港股上市，全球发售约6.32亿股H股，另有15%超额配股权，发行价为21.30港元/股。此次IPO招股引入21名基石投资者，合共认购7.59亿美元的发售股份，基石投资者包括淡马锡、贝莱德、盈峰资本、高瓴、瑞银资管、LMR、RBC GAM、WT、橡树资本、睿远基金、高毅、景林、保银、Ghisallo、Jane Street、Fenghe、Qube、潍柴动力、大家保险、法士特、惠理基金，充分彰显了国际资本市场对三一重工的强烈信心和高度认可。自成立以来，三一重工通过内生发展、战略收购以及合资合作的方式，从单一品类、单一国家运营，转型升级为多元化产品、全球化运营的世界级工程机械行业领军企业。目前，三一重工正全面推进"全球化、数智化、低碳化"三大战略。全球化方面，据弗若斯特沙利文的报告，按2020年至2024年核心工程机械产品的累计收入计算，三一重工是全球第三、中国最大的工程机械企业。公司产品远销全球150余个国家和地区，2020年至2024年，挖掘机累计销量全球第一，混凝土机械累计收入全球第一。2022年至2024年，公司海外收入复合年增长率高达15.2%，全球化运营能力领跑行业。数智化方面，三一重工通过数智化赋能制造、运营、服务全流程，实现质量精进及效率突破。其中，公司聚焦先进制造技术，对工厂进行数智化升级，构建全球领先的制造竞争力。截至2025年4月30日，三一重工是全球工程机械行业唯一一家拥有2座世界经济论坛认证灯塔工厂的企业，即北京桩机工厂和长沙18号工厂，为全球制造业企业提供可借鉴的数智化发展方向。低碳化方面，三一重工已跻身全球低碳化程度最为领先的工程机械企业之一。2024年，公司40余款新能源产品成功上市，包括挖掘机、装载机、泵车、搅拌车、起重机等，来自于新能源工程机械产品的收入约为人民币40.25亿元，收入贡献比例大幅超过全球行业平均水平。公司电动挖掘机、电动搅拌车、电动自卸车等新能源产品销量均位居中国第一。以港股上市为契机，三一重工将进一步深化三大核心战略，坚持全球化战略，更好地满足全球客户需求；继续推进数智化转型，全方位赋能公司竞争力提升；持续践行低碳化战略，构建可持续未来。风劲潮涌，自当扬帆破浪；任重道远，更需策马扬鞭。让我们共同见证，三一重工在全球经济的广阔海域中劈波斩浪，驶向更加辉煌的明天！ Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月28日 - (亚太商訊) - 2025年10月28日，权威管理咨询机构久谦咨询发布全球全景及运动相机市场研究报告。报告指出，近年全球运动相机与全景相机市场份额出现显著变化，市场格局正经历快速重构。在运动相机领域，曾经占据全球主导地位的是美国品牌GoPro，2022-23年，GoPro依靠HERO系列稳居头部，全球市场占有率75%以上，但到2025年其收入占全球市场份额已逐步收缩至18%。而经过三年，市场迎来"新王"——大疆凭借多年战略布局、产品节奏及生态协同，快速崛起，到2025年Q3大疆在这个领域的收入占全球市场份额已达66%，以绝对优势成为全球运动相机市场第一。另一中国品牌影石目前则占据约13%的市场份额。全景相机的市场格局也迎来激烈变动。大疆于今年7月31日入局该领域，在不到三个月的时间内，其首款全景相机Osmo360，凭借跨端应用与高性价比的优势，分别在中国电商渠道获得了49%的市场份额，全球市场份额达43%。加速推动全球全景相机市场格局重构。最近京东"运动相机金榜"出炉，也见证了整个运动相机赛道，已经彻底进入"大疆时间"。大疆Osmo Action 5 Pro、大疆Osmo Nano、大疆Osmo Action 4三款产品直接包揽运动相机金榜前三。从更详细的市场表现上看，在京东"户外全景运动相机热卖榜"中，大疆Osmo 360发布接近不到3个月也夺得榜首，且已经在此领域上占据了49天的位置。大疆在运动相机和全景相机的市占和销量数据，不仅是中国品牌科技硬实力的证明，也显示大疆在原来占据绝对优势的无人机行业之外，以持续成长的影像技术矩阵及生态布局，在全球手持影像市场也取得了绝对优势领跑的地位。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - The International Leo Tolstoy Peace Prize Jury announced the 2025 laureates in recognition of outstanding efforts contributing to regional harmony and security in Central Asia. The award honors the signing of the Treaty on the Junction Point of State Borders and the Khujand Declaration of Eternal Friendship in Khujand, Tajikistan, on March 31, 2025 — landmark agreements that strengthen legal frameworks for mutual trust and cross-border collaboration.Established on June 22, 2022, by the Russian Historical Society, the Russian Peace Foundation, and the Russian Military Historical Society, the International Leo Tolstoy Peace Prize Foundation convenes juries including prominent figures from Argentina, Belarus, India, China, Russia, France, South Africa, and Japan. Jury Chairman Valery Gergiev, renowned conductor and artistic director of the Mariinsky Theatre, emphasized the prize’s mission to “advance global understanding and mutual respect.” He noted the growing reach of the peace movement inspired by Russian writer-philosopher Leo Tolstoy, expressing hope that the prize could, like music, “help nations listen and truly hear one another.”The 2025 honor celebrates the joint efforts of:- Sadyr Japarov, Kyrgyz Republic- Emomali Rahmon, Republic of Tajikistan- Shavkat Mirziyoyev, Republic of UzbekistanTheir collaboration has strengthened stability, sustainable growth, and the international profile of Central Asia. The award ceremony date will be announced soon.About the PrizeThe International Leo Tolstoy Peace Prize is awarded by an international jury established by the founders of the L.N. Tolstoy International Peace Prize Foundation. The jury is composed of distinguished Russian and foreign figures of recognized international standing and moral authority.Candidates for the Prize may include individuals, initiative groups, national and international public foundations, organizations, movements, scientific and research centers, as well as educational institutions. Self-nomination is not permitted; however, nominators are encouraged to publicly discuss the candidates they propose. Rooted in the humanist ideals of Leo Tolstoy, the Prize honors those whose work embodies the pursuit of peace, moral integrity, and shared progress for humanity.Media contactOrganization: The International Leo Tolstoy Peace PrizeContact: Media teamWebsite: https://tolstoypeaceprize.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.More Information about LUCENTIS® and Ocular Neovascular DiseasesLucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].More Information about BEOVU® and the DME IndicationBeovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.About NOVARTISNovartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Product-related information can be found on the Novartis website at:https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications 2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 4. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).5. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.8. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.9. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics"ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materials they need for robust and efficient drug development."CIL's global manufacturing network, including facilities in North America, Europe, and Asia, enables CIL to provide a diversified and resilient supply chain for pharmaceutical partners. Every ISOAPI-D product is manufactured in ISO 9001-certified facilities, ensuring the highest standards of quality, regulatory compliance, and full traceability throughout the production process.A core component of the ISOAPI-D line is heavy water (D₂O), which is sourced exclusively from approved suppliers. This product is fully traceable and tritium-free, aligning with stringent safety and regulatory requirements of the pharmaceutical industry.The ISOAPI-D range also features advanced intermediates that allow for more streamlined synthetic pathways. By reducing the number of synthesis steps and optimizing production efficiency, these intermediates can help lower manufacturing costs and accelerate the time to market for new therapeutics.Since 1981, CIL has been a trusted supplier of premium deuterated materials to leading pharmaceutical and biotechnology companies worldwide. This longstanding commitment to quality and reliability continues with the launch of ISOAPI-D, offering customers a secure, high-quality supply of essential reagents and reducing operational risk in their development pipelines."ISOAPI-D represents the next step in our ongoing mission to support pharmaceutical innovation," said Tasha Agreste, Business Development Manager Deuterated Reagent Applications, at CIL. "Our expanded manufacturing capabilities, rigorous quality standards, and decades of experience position CIL as a reliable partner for the industry's evolving needs."Visit CIL at CPhI Frankfurt, Stand #2.0G2, October 28-30, to discover ISOAPI-D, the future of deuterated chemistry for pharmaceuticals.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds.Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA AND HYDERABAD, INDIA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continuity. The forthcoming entity, Cambridge Isotope Laboratories, Pvt. Ltd., is expected to be officially established in Q4 2025, subject to customary diligence and closing considerations. Operations for the newly formed entity will be initiated at existing CCS facilities, with a net new facility slated for groundbreaking in 2026. The new facility will be located in India's Genome Valley, a burgeoning 2,000-acre life sciences cluster located in suburban Hyderabad.Cliff Caldwell, CEO at CIL noted, "We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields as well as supporting the growing commercial needs for deuterium labeled and specialty chemical products in the pharmaceutical and electronics industries."Vishal Rajput, CEO of CCS said, "The collaboration and newly formed entity will leverage CCS's strong infrastructure and deep technical capabilities in India, while integrating CIL's world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities." Mr. Rajput will lead the newly formed entity as general manager of Cambridge Isotope Laboratories, Pvt. Ltd. The legacy CCS business will remain intact, with the collective intent to expand access to high quality, isotopically labeled and unlabeled compounds for customers worldwide, with an emphasis on downstream synthetic compounds and a commitment to industry-specific product quality requirements.All CIL, Eurisotop and CCS branded and manufactured materials remain available to Indian and worldwide customers through existing channels. Further details regarding the launch and operational scope of Cambridge Isotope Labs Pvt. Ltd. will be shared in the coming months.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds. Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.About Chemtatva Chiral Solutions, Pvt. Ltd.CCS is a Hyderabad-based company founded in 2021, specializing in chiral chemistry, process development, and custom synthesis for pharmaceutical and chemical industries. CCS is a trusted global partner in life sciences, delivering innovative chemistry solutions that solve complex challenges and accelerate scientific progress.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年10月27日 - (亚太商訊) - 康哲药业控股有限公司（"康哲药业"）欣然宣布，于2025年10月27日，康哲药业通过子公司CMS VISION INTERNATIONAL MANAGEMENT LIMITED与Novartis Pharma Services AG （"诺华"）就雷珠单抗注射液（"诺适得(R)"）、布西珠单抗注射液（"倍优适(R)"）签订经销协议（"协议"）。根据协议，康哲药业获得产品在中华人民共和国（为协议之目的，不含香港特别行政区、澳门特别行政区、台湾）的协议所约定之独家进口、经销、销售、推广权利；诺华继续负责生产、供应产品。合作期限为协议约定的生效日起五年。两款合作产品均已在中国获批上市，其中诺适得(R)是中国首个获批用于眼科的抗血管内皮生长因子（VEGF）药物，具备成熟的临床应用经验，为众多眼底疾病患者提供了可靠保障；诺适得(R)已被批准用于治疗湿性年龄相关性黄斑变性（nAMD）、糖尿病性黄斑水肿(DME)、视网膜静脉阻塞(RVO)继发的黄斑水肿等多项眼底新生血管性疾病。另一款产品倍优适(R)为新一代抗VEGF药物，2025年5月中国获批用于DME，其凭借独特的超小分子（仅26kDa）、高浓度创新优势，显著改善视网膜解剖学结构，助力更多DME患者获得视力改善，减轻治疗负担。康哲药业眼科业务公司"康哲维盛"专注于在全球范围内布局、开发临床急需的眼科药械创新产品，致力于打造"中国眼科医药龙头"，此次合作将提升康哲维盛在眼科领域的整体竞争力。康哲维盛已覆盖眼底疾病、视疲劳、青光眼等眼科疾病领域，诺适得(R)及倍优适(R)加入后，将与在售独家药施图伦滴眼液（七叶洋地黄双苷滴眼液）、在售独家医疗器械EyeOP1青光眼治疗仪在客户、专家资源、渠道网络上产生高度协同，提升康哲维盛在眼科领域的学术品牌竞争力，为持续合作、开发临床急需的眼科创新产品带来正向推动作用，为眼科疾病患者提供更多元化的治疗选择。同时康哲维盛专业的眼科团队将整合市场渠道与学术资源，提升团队整体效能，并预期对康哲药业业绩产生积极正面影响。关于诺适得(R)及眼底新生血管性疾病的更多信息诺适得(R)是重组抗VEGF人源化单克隆抗体Fab片段，靶向抑制人血管内皮生长因子A（VEGF-A），以抑制血管内皮细胞增殖、新生血管生成和血管渗漏。诺适得(R)作为中国首个获批用于眼科的抗VEGF药物[3]，自2011年在中国上市以来，已被批准用于治疗多项眼底新生血管性疾病，包括nAMD、DME、RVO继发的黄斑水肿、脉络膜新生血管(CNV)、糖尿病视网膜病变（DR）、早产儿视网膜病变(ROP)。诺适得(R)已于2017年被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》，具备成熟的临床应用经验，为众多眼底疾病患者提供了可靠保障。眼底新生血管性疾病是一类以血管通透性增加、血管渗漏以及血管完整性的缺失为特征的严重致盲性眼病，主要包括nAMD、DR、DME、RVO、CNV、ROP等。抗VEGF药物是多个权威指南推荐治疗眼底新生血管性疾病的一线疗法[3, 4]。根据弗若斯特沙利文报告，中国眼底新生血管性疾病患者预计将从2019年的47.8百万人增至2030年的61.2百万人。中国抗VEGF眼科药物市场预期将从2019年的24亿元增长至2030年的186亿元。根据《抗VEGF药物治疗眼底新生血管性疾病》，诺适得(R)作为中国首个获批用于治疗眼底新生血管性疾病的抗VEGF药物，在多项临床试验中均显示出良好的安全性和有效性，已被广泛应用于治疗眼底新生血管性疾病，它的问世代表了眼科临床治疗的一个重大进步[5]。关于倍优适(R)及DME适应症的更多信息倍优适(R)是一种靶向VEGF-A的新型人源化单链抗体片段，已于2025年5月获得中国国家药品监督管理局批准用于DME。作为目前分子量最小的抗VEGF药物（仅26kDa），倍优适(R)治疗DME负荷期每6周给药一次（其他抗VEGF药物负荷期每4周给药1次），维持期每2至3个月给药一次。倍优适(R)针对初治DME患者的全球3期KESTREL和KITE研究均达到主要疗效终点且视力获益持续至100周。倍优适(R)6mg组患者IRF（视网膜内积液）和/或SRF（视网膜下积液）更少。倍优适(R)首年中位注射次数（7次）少于阿柏西普（9次），同时总体安全性与后者相当[6]。中国真实世界研究BEST研究显示，经治不达标的DME患者经倍优适(R)首针治疗1周后BCVA即较基线提升6.1字母，注射第3针（12周）提升10字母，倍优适(R)为经治DME提供更优化的治疗选择[7]。DME是由于黄斑区毛细血管渗漏所致的视网膜增厚，是血视网膜屏障破坏的结果，主要影响中心视力[8]。据弗若斯特沙利文报告，2025年中国约有7.89百万例DME患者。但即使按目前规范的抗VEGF药物治疗方案，仍有约30%-50%DME患者积液控制不佳[9-11]。《2022中国常见眼底病慢病管理现状白皮书》调研显示，我国患者治疗依从性较差，30%以上DME患者未能完成负荷期治疗。临床亟需更强效、更持久、依从性更高的治疗药物以改善DME患者的诊疗现状。新一代抗VEGF药物倍优适(R)为解决这一难题提供了潜在方法，其凭借独特的超小分子、高浓度创新优势，显著改善视网膜解剖学结构，助力更多DME患者获得视力改善，减轻治疗负担。关于诺华诺华是一家全球知名的医药企业，总部位于瑞士巴塞尔。诺华聚焦患者需求紧迫的四大核心治疗领域（心血管、肾脏及代谢，肿瘤，免疫，神经科学）以及五大关键技术平台（化学疗法、生物疗法、xRNA疗法、放射配体疗法、基因和细胞疗法）。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 产品相关信息可在诺华官网查询，网址：https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications2. Lim, Jennifer I et al. "Diabetic Retinopathy Preferred Practice Pattern(R)." Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. 中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病学组.中国年龄相关性黄斑变性临床诊疗指南(2023年)[J].中华眼科杂志,2023,59(5):347-366.4. 许迅,王建影.疾病谱变化驱动临床药物更迭[N].健康报,2023-07-05(005).5. 侯慧敏,常雪柯,靳雨佳,等.抗VEGF药物治疗眼底新生血管性疾病[J].国际眼科纵览,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diaßbetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. 余洪华，2025中国眼底病论坛暨国际视网膜研讨会，6月4日-7日，中国无锡8. 中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)[J]. 中华眼底病杂志,2023,39(2):99-124.9. 戴虹, 卢颖毅. 糖尿病黄斑水肿治疗策略的变化与面临的问题[J].中华眼底病杂志, 2022, 38(1): 6-9.10. Bressler, Neil M et al. "Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial." JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. "Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data." Eye (London, England) vol. 31,11 (2017): 1594-1599.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – CTF Life today announced the signing of a Memorandum of Understanding with Gleneagles Hospital Hong Kong (“Gleneagles”), CUHK Medical Centre (“CUHKMC”), and Hong Kong Baptist Hospital (“HKBH”) to establish strategic partnerships. In a pioneering move, CTF Life has also become the first insurance company to collaborate with Gleneagles MediCentre in Admiralty to launch an exclusive programme to provide customers with health management solutions. At the same time, the PrimeChamp Doctor Network has been enhanced with the official inclusion of the three hospitals and their affiliated medical centres. This expanded medical network now spans across Hong Kong, offering customers priority referrals, appointment scheduling and direct billing services.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “We are pleased to forge long-term business partnerships with three leading and distinguished hospitals. Harnessing the strengths of the Chow Tai Fook Group ecosystem, we are committed to providing our customers with more flexible and superior medical service solutions, serving as their Life Planner. This collaboration not only further solidifies our medical network across Hong Kong, but also elevates the overall service experience at CTF Life, empowering customers with greater autonomy, convenience and comprehensive medical service experiences at every stage of their life journey. We firmly believe that medical protection should go beyond claims, it should accompany our customers across every stage from prevention and diagnosis to treatment and recovery, truly bringing to life our vision of creating value beyond healthcare.”Territory-wide Medical Network Coverage Across Hong KongThe three hospitals will respectively serve as CTF Life’s designated medical network partners on Hong Kong Island, Kowloon, and the New Territories. Their doctors and mental health therapists will also join the PrimeChamp Doctor Network, providing customers with convenient, high-quality, and comprehensive medical services.Hong Kong Island: Gleneagles Hospital Hong KongGleneagles serves as the appointed medical network partner for Hong Kong Island. CTF Life has also become the first insurance company to collaborate with the newly opened Gleneagles MediCentre in Admiralty, further expanding its service scope through exclusive programmes. These programmes include gastroscopy, colonoscopy and wart removal services, providing customers with prevention-oriented health management solutions.New Territories: CUHK Medical CentreCUHKMC will serve as the selected medical network partner for the New Territories. Backed by a top-tier medical team comprising professors from the CUHK Faculty of Medicine and specialists, coupled with advanced medical facilities and strong research capabilities, CUHKMC provides customers with premium, multi-specialty medical services. Dedicated to translating cutting-edge international medical research into clinical practice, CUHKMC delivers a world-class diagnostic and treatment experience that benefits both customers and the wider community.Kowloon: Hong Kong Baptist HospitalHKBH will serve as the designated medical network partner for Kowloon.  Operating under a “One Hospital, Multiple Service Sites” synergy model, the hospital enables patients to conveniently access medical services close to their preferred location. Among these sites, the HKBH East Kowloon Medical Centre (EKMC), located in the Kwun Tong Business District (Ngau Tau Kok), provides pre-approved direct billing services for cataract surgery and oncology treatments. Additionally, mental health team offers professional guidance to help individuals better understand and manage their psychological well-being. Together, these services embrace the Hospital mission: “In the Service of Man, for the Glory of God.”Customer-Exclusive Medical Services Reflects a People-Centric ApproachThrough this collaboration, the three hospitals will offer the following services for CTF Life customers:- Priority referral and appointment scheduling, significantly reducing waiting time.- Direct billing services, allowing customers to receive treatment without upfront payment, easing financial pressure.- One-stop cancer treatment services, covering diagnosis, treatment, and post-surgery rehabilitation, providing comprehensive support throughout the care journey.- Access to premium medical services and coordination, arranging professor-level doctors and advanced medical facilities to ensure customers receive the highest quality of medical care.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (middle); Ellick Tsui, Executive Director, Deputy Chief Executive Officer and Chief Financial Officer of CTF Life (second from right); Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (second from left); Dr Chung Kin Lai, Chief Executive Officer of CUHK Medical Centre (first from right); and Dr Leung Chi Bon, Chief Executive Officer of Hong Kong Baptist Hospital (first from left), announce the establishment of strategic partnerships at the kick-off ceremony.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.Media enquiriesCTF LifeCorporate Communications DepartmentVecinia Lau+852 2591 8297vecinia.lau@ctflife.com.hk Chow Tai Fook Life Insurance Company Limited (Incorporated in Bermuda with limited liability) Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月27日 - (亚太商訊) - 周大福人寿今日宣布，与港怡医院、香港中文大学医院（「中大医院」）及香港浸信会医院（「浸会医院」）签署合作备忘录，建立策略性合作伙伴关系。周大福人寿更成为首间保险公司与港怡医院其位于金钟之日间医疗中心合作推出专属计划，为客户提供健康管理方案。同时，「尚逸医生网络」全面升级，三家医院及其附属医疗中心正式加入，组成更强大的医疗网络，覆盖全港，为客户提供优先转介、预约及直接结算服务。周大福人寿执行董事兼行政总裁叶文杰表示：「我们非常高兴与三家具领导地位的卓越医院建立长远合作关系，透过周大福集团生态圈的优势，为客户提供更灵活和优质的医疗服务方案，成为他们的人生规划师 。是次合作不仅进一步巩固我们全港的医疗网络，同时亦进一步提升了周大福人寿的服务质量，让客户在不同人生阶段，能享有更自主、便捷和全面的医疗服务体验。我们坚信，医疗保障不应止于理赔，应延伸至预防、诊断、治疗及康复的每一个阶段，真正实践开创健康新价值。」三区医疗网络布局　实现全港覆盖三家医院将分别成为周大福人寿于港岛、九龙、新界区的指定医疗网络，医院医生及心理健康治疗师亦会加入「尚逸医生网络」，为客户提供便捷、优质和全面的医疗服务。港岛区：港怡医院港怡医院是港岛区的指定医疗网络。为进一步扩展服务范畴，周大福人寿更成为首间保险公司与港怡医院位于金钟、新开幕之港怡日间医疗中心合作，推出涵盖「肠胃镜检查」及「疣切除」的专属计划，为客户提供以预防为本的健康管理方案。新界区：中大医院中大医院将成为新界区的指定医疗网络。中大医院拥有由中大医学院教授及专科医生组成的顶尖医护团队，再配合其先进的医疗设施与科研实力，为客户提供涵盖多个专科的高端医疗服务。医院致力将国际前沿医研成果转化为临床服务，为客户带来世界级的诊疗体验，惠及社会大众。九龙区：浸会医院浸会医院将成为九龙区的指定医疗网络。浸会医院采用「一院多点」的营运模式，让客户能够就近获得所需医疗服务。其中，位于观塘商贸区（牛头角）的浸信会东九龙医疗中心（EKMC）提供白内障手术及肿瘤科预先批核直付服务; 其心理健康治疗师团队亦会为客户提供身心灵全方位的照顾，秉持着「全人医治．荣神益人」的精神。客户专属医疗服务 体现以人为本精神透过是次合作，三家医院将为周大福人寿客户提供以下服务：- 优先转介及预约安排，大幅缩短轮候时间- 直接结算服务，客户无需预先垫支医疗费用，减轻财务压力- 一站式癌症治疗服务，涵盖诊断、治疗、及术后康复，全程支援照顾- 高端医疗对接，为尊贵客户安排教授级医生及先进医疗设施，确保最优质的医疗照顾周大福人寿执行董事兼行政总裁叶文杰 (中) 、周大福人寿执行董事兼副行政总裁暨首席财务官徐志坚(右二)  、IHH医疗 (北亚洲) 区域首席执行官兼港怡医院执行总裁曾庆亷医生(左二)、香港中文大学医院行政总裁钟健礼医生(右一) 以及香港浸信会医院行政总监梁志邦医生(左一) 出席启动礼，宣布周大福人寿与三大医院建立策略性合作伙伴关系。关于周大福人寿 周大福人寿保险有限公司（「周大福人寿」）扎根香港40年，为周大福创建有限公司（「周大福创建」）（香港股份代号：659）的全资附属公司，也是香港最具规模的寿险公司之一。作为周大福企业成员，周大福人寿紧扣郑氏家族（「周大福集团」或「集团」）生态圈的雄厚资源，致力为客户及其挚爱于「生活、成长、健康、传承」的人生旅程中，提供个人化的匠心规划、终身保障及优质体验。凭借集团财务实力及环球投资布局，周大福人寿矢志成为亚太区领先的保险公司，持续开创保险新价值。传媒联络周大福人寿企业传讯部柳丽凤+852 2591 8297vecinia.lau@ctflife.com.hk周大福人寿保险有限公司（于百慕达注册成立之有限公司） Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com